GlassScriptPhysician profile
Eoin Donnellan
NPI 1225437528
$48,130.87
in general payments reported to CMS, 2019-2025
22 companies · $3,387 in 2025
The $3,387 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,490 · 2020: $9,174 · 2021: $7,280 · 2022: $4,792 · 2023: $14K · 2024: $5,244 · 2025: $3,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,623 · Food and Beverage: $7,272 · Consulting Fee: $3,800 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,622.50 |
| Food and Beverage | $7,271.70 |
| Consulting Fee | $3,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18,894.37 | 2019-2025 | Aveir, Gallant, Ensite |
| Medtronic, INC. | $6,470.62 | 2021-2025 | Diamondtemp Bidirectional Ablation Catheter, Micra, Aurora Ev-Icd Mri Surescan |
| Atricure, INC. | $6,035.98 | 2023 | |
| Boston Scientific Corporation | $5,490.73 | 2019-2025 | Watchman Access System, Farapulse, Watchman Flx |
| Medtronic Vascular, INC. | $4,954.36 | 2019-2020 | |
| Biotronik INC. | $4,788.23 | 2022-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Biosense Webster, INC. | $435.13 | 2023-2025 | Carto 3, Qdot Micro Catheter, Thermocool Smarttouch |
| Abiomed | $242.42 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.02 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $131.00 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiva Medical, INC. | $113.97 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Novartis Pharmaceuticals Corporation | $92.96 | 2024-2025 | |
| Novo Nordisk INC | $90.96 | 2023-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $74.02 | 2023-2024 | Xarelto |
| Shockwave Medical, INC | $25.02 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.02 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.02 | 2025 | Jardiance |
| Ethicon US, LLC | $19.65 | 2025 | Stratafix |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2024 | Farxiga |
| Terumo Medical Corporation | $16.23 | 2024 | Metacross Otw |
| Scpharmaceuticals INC. | $15.37 | 2024 | |
| Lilly USA, LLC | $14.64 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eoin Donnellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.